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ABSTRACT
The latest epidemiological data in Spain were obtained a decade ago and revealed a 
prevalence of hepatitis B surface antigen (HBsAg) of 0.7%; hence, updated 
epidemiological data is necessary. Our aim was to determine the prevalence of hepatitis 
B virus (HBV) infection, as well as to analyse associated factors and characterize chronic 
infection. A population-based, cross-sectional study was performed in Spain between 
July 2015 and April 2017. Participants from 3 regions were selected using two-stage 
conglomerate sampling and stratified by age. Anthropometric and demographic data 
were collected, and blood samples taken to detect serological markers of HBV infection 
and to quantify HBV-DNA. The characterization of chronic HBV infection was based on 
ALT (alanine aminotransferase) values, HBV-DNA levels, and results of transient 
elastography. The overall prevalence rates of HBsAg and antibody to hepatitis B core 
antigen (anti-HBc) among 12,246 participants aged 20–74 years (58.4% females) were 
0.6% [95% CI (0.4-0.7)], and 8.2% (7.7-8.7), respectively. The risk factors for HBV 
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Spanish nationality. Moreover, most patients HBsAg positive (76.6%) presented as 
hepatitis B e antigen (HBeAg) negative chronic infection (formerly “inactive carriers”) and 
only 6 (9.4%) HBsAg carriers fulfilled current criteria for treatment. The current HBV 
burden in Spain remains low but virtually unchanged over the past 15 years. Increased 
efforts are still needed to reach the goal set forth by the World Health Organization 
(WHO) for HBV elimination by 2030. 
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INTRODUCTION
Chronic hepatitis B virus (HBV) infection remains a major health threat with 
approximately 250 million carriers worldwide many of them being at risk of developing 
cirrhosis and even hepatocellular carcinoma.1 There is great variability on a global scale 
regarding HBV chronic infection being Spain a low-endemic southern European country.1 
The implementation of vaccination programs against HBV, along with other primary 
prevention measures, including health care infection control and antenatal screening, 
have led to a decrease in the incidence of acute and chronic hepatitis B (CHB) in many 
European Union (EU) countries.1,2 However, migration is currently changing the 
prevalence of HBV in several low endemic countries due to higher HBsAg prevalence 
rates in migrants and refugees from outside Europe.1 
In 2016, the World Health Assembly passed a resolution to eliminate viral hepatitis as a 
public health threat by 2030.3 The targets include 90% global coverage of three-dose 
infant vaccination by 2020, diagnosis of 90% of people infected with HBV, and antiviral 
treatment of 80% of those diagnosed with HBV and eligible for treatment. Timely, reliable 
prevalence data are needed to identify the populations that are most affected in order to 
improve screening and treatment programmes and to monitor the performance and 
impact of these activities at a strategic level. There are some recent epidemiological 
reports in different regions worldwide, including countries in southern and western 
Europe with low prevalence, that indicate a decline in average HBsAg prevalence rates to 
0.6%, or even 0.3% in Spain.1,2 However, these reports are based on estimates from 
systematic reviews of peer-reviewed literature on HBV prevalence in the general 
population. Population-based studies are necessary to confirm these estimates and 
update the latest epidemiological data in Spain that come from studies carried out in the 
first decade of this century, which showed HBsAg prevalence figures of 0.7%.4,5
The aim of this study was to update the current burden of HBV infection in Spain, to 
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MATERIALS AND METHODS
This observational, cross-sectional, population-based study on HBV and HCV infections 
was carried out in Spain between July 2015 and April 2017 (NCT02749864). The design 
of the study and the results regarding HCV infection have been previously published.6 
The cohort of patients with positive HbsAg was retrospectively analyzed to adequately 
characterize the infection. Overall 12,263 subjects aged between 20 and 74 years old 
were estimated to participate; they were stratified in three age cohorts (20-34 yr., 35-49 
yr., and 50-74 yr.) according to the different expected prevalence. An uptake of 9−15%, 
via telephone invitation was estimated. Recruitment was made through a structured 
phone call that allowed collecting anonymous data from those who declined. Participants 
underwent a physical examination and were invited to complete a self-reporting 
questionnaire that was supervised to decrease the missing values (Table S1). 
Blood samples were collected for complete blood count, biochemistry, and serological 
markers, and they were stored in the Valdecilla Biobank. The presence of HBsAg, and 
antibody to hepatitis B core antigen (anti-HBc) were assessed by immunoassay 
(ARCHITECT-i2000SR, Abbott Laboratories, Germany). In HBsAg positive patients, the 
HBV-DNA blood levels were measured using real-time polymerase chain reaction (PCR) 
and quantified using the automatic COBAS TaqMan HBV Test 2.0 equipment (15 IU/mL 
sensitivity). Abdominal ultrasound and transient elastography (FibroScan-Echosens) 
were performed to determine liver stiffness in HbsAg positive patients.
A descriptive analysis was performed. The adjusted association with the anti-HBV 
seroprevalence was investigated with a logistic regression analysis by introducing 
variables that were related to anti-HBV seroprevalence in a univariate analysis (P<0.1), 
or that were considered clinically relevant regardless of statistical significance. The 
strength of association was estimated using the odds ratio (OR) with 95% CI. Analyses 
were performed using SPSS Statistics for Windows, Version 21·0 (IBM Corp, Chicago, 
USA). All the P-values were two-tailed, with statistical significance defined as P<0·05. 
The Institutional Review Board (IRB) of Cantabria approved this study on March 13, 
2015, and it was conducted in compliance with the Declaration of Helsinki of 1975 and 
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RESULTS
12,246 participants were recruited, which represents 22.8% of recruitment success 
(Figure 1). 83.5% of those who declined to participate answered a questionnaire. 
Significant differences between these 2 groups were observed according to the 
respondent’s age, sex, and level of education (Table S2). However, only differences in 
the educational level seemed to discriminate between both groups, with 1.5 times more 
subjects presenting lower education levels in the group that declined to participate 
[51.6% vs. 35.0% (p<0.001)].
Participants were predominantly female (58.3%), Spanish nationals (93.7%), employed 
(56.7%), and with middle-upper levels of education (65%) [Table S3]. The most common, 
self-reported HBV risk factor among subjects was nosocomial risk (79.2%) [Tables S3-
S4). Up to 23% of the general population presented abnormal alanine aminotransferase 
levels. 
Overall, 67 in 12,246 individuals analysed were HBsAg positive, which accounts for a 
prevalence of 0.6% [95% CI (0.4-0.7)], with infection rates highest in older subjects 
(Table S5; Figure S1); anti-HBc seroprevalence was 8.2% (7.7-8.7). 46.3% of HBsAg 
positive patients were already aware of their serological status (Figure S2). Factors that 
were significantly associated with HBsAg detection in the multivariate analysis were age, 
non-Spanish nationality, and nosocomial risk (Table S6). Eleven of 67 (16.4%) HBsAg 
positive patients were not born in Spain, which equates to a prevalence of infection of 
1.4% (95% CI 0.8-2.5) in this population whereas the anti-HBc seroprevalence was 12.0 
(93/772; CI 95% 9.9-14.5) (Figures S3-S4). Table S7 shows the variables associated 
with the risk of having detectable anti-HBc. 
Two HBsAg positive patients were lost to follow-up and their hepatitis B e antigen 
(HBeAg) status could not be assessed; another patient presented as an acute co-
infection human inmunodeficiency virus (HIV)-HBV that was treated accordingly (Table 
S8; Figure 1). Six in 64 [9.4% (95% CI 4.4-18.9)] patients were HBeAg positive/AntiHBe 
negative; all of them corresponded to chronic infection.7 Alternatively, 58 in 64 [90.6% 
(95% CI 81.0-95.6)] patients were HBeAg negative/anti-HBe positive. Overall, 49 of these 
patients (84.5%) were identified in a chronic infection phase (formerly “inactive carrier”), 
whereas 5 (8.6%) were recruited in a chronic hepatitis phase and the remaining 4 
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carriers fulfilled current criteria for treatment (Figure 1). Most patients had low-grade 
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DISCUSSION
Updated HBV sero-prevalence rates were 0.6% and 8.2% for HBsAg and anti-HBc 
respectively in Spain. The risk factors for HBV infection were age, nosocomial risk, and 
non-Spanish nationality. Moreover, a majority of HBsAg positive patients (76.6%) 
presented as HBeAg negative chronic infection (formerly “inactive carriers”), and only 6 
(9.4%) HBsAg carriers fulfilled current criteria for treatment.  
The most recent data regarding HBV prevalence in Spain based on systematic reviews or 
modelling studies reveal discrepant rates (0.34% to 0.60%) that may impact the planning 
of health and financial resources.1,2 Our results are closer to the latest estimation from 
the recent modelling study of the Polaris Observatory, which accounts for approximately 
190,000 chronically infected patients in the age range studied.2 Interestingly, data from 
our study are practically identical to the data obtained 10-15 years ago in two large-scale 
population-based studies carried out in Spain.4,5 They revealed a substantial reduction in 
the global prevalence of HBsAg (from 1.5% to 0.7% in the period 1989-2002) and later a 
stabilization (2002-2010). Indeed, measures like the introduction of the vaccination 
calendar in the 90s, the systematic control of donations of blood, or the screening in 
pregnants have contributed to the decreased incidence of HBV in Spain as in other 
developed countries in recent years.4,5 However, a plateau phase (or at least a 
slowdown) in the dropping curve of HBsAg prevalence appears to have occurred. We 
could hypothesize that the beneficial effect of vaccination was “discounted” in the latest 
aforementioned epidemiological studies and there are still a considerable amount of 
people who have not benefited from this program due to their age. Furthermore, an 
increase in the immigrant population could partially account for this effect, which appears 
to be reinforced in this study where the prevalence of HbsAg in the immigrant population 
was more than twice as high as in the general population. Finally, it is possible that 
facilitation in the access to better antiviral therapies that preclude the evolution to more 
advanced stages of the disease can explain greater survival rates and, therefore, the 
maintenance of prevalence rates. Taking into account the demographic evolution of the 
European population towards aging and an increase in the immigrant population these 
results support the need to intensify screening programs in these groups. 
A complete characterization of CHB according to levels of serum ALT and HBV-DNA, as 
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making regarding treatment initiation as well as treatment response. In Spain, an 
evaluation from 396 HBV mono-infected HBsAg positive patients in 1999 revealed that 
67% of these were “inactive carriers”, whereas 33% presented as chronic hepatitis.8 The 
study also showed that most CHB infections were antiHBe positive (86%), and only 16% 
of these fulfilled criteria to initiate treatment. Our study confirms the predominance of anti-
HBe positive patients and also that only a very small percentage of patients require 
treatment based on current guidelines.7 These guidelines do not support generalized 
treatment for all carriers due to the slow rate of progression of the disease, relative low 
likelihood of carcinogenesis in occidental countries, and possibly due to the cost and 
limitations of current treatments. Meanwhile, increasing the efforts in universal 
vaccination worldwide, increasing the number of educational campaigns to avoid new 
infections, screening people at risk (i.e. older than 45-50 years old and immigrants from 
countries of high prevalence), and possibly expanding current treatment criteria could 
help to eliminate this viral infection.
The study has some limitations that could involve selection and participation bias that 
have been previously discussed.6 We cannot rule out some misclassification in the stage 
of infection due to the study design. The sample size calculation was based on estimated 
slightly higher values of the prevalence figures for each age stratum;6 therefore, a larger 
number of subjects was studied, which helps provide a more accurate estimation of the 
parameters.
 
In conclusion, the current HBV burden in In Spain remains relatively low but virtually 
unchanged in the last 15 years. Many efforts are still needed (educational, preventive, 
screening in at-risk populations, treatment and drug research) to reach the WHO 
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TABLES
FIGURE LEGENDS
Figure 1. Flow-chart of the study and characterization of HBsAg infected patients.
FSU, first-stage units; IC, informed consent; and SSU, second-stage units.
†HBeAg status could not be assessed; ‡The patient presented an acute co-infection HIV 
and HBV at the time of recruitment. He showed HBsAg seroconversion on HAART 
treatment that included tenofovir. §HBeAg patients could not be fully characterized due to 
the unavailability of either HBV-DNA or ET (Fibroscan®). ¶4 in 5 patients HBeAg negative 
with chronic hepatitis B were already undergoing treatment at the time of recruitment, 
whereas the other patient started the treatment after being diagnosed during the study. 
Another patient with HBeAg negative chronic infection was being treated due to the risk 
of HBV transmission as a health profesional worker. 
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